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CORRESPONDENCE
‘Plan B’ for X-ray 
astronomy 
The European Space Agency 
(ESA) decision to go ahead 
without NASA support in 
selecting its next large astronomy 
mission (Nature 471, 421; 
2011) has dashed hopes for the 
International X-ray Observatory 
(IXO). X-ray astronomy needs a 
cheaper ‘plan B’. 
NASA might yet contribute 
20% of the funding for a smaller 
IXO, but that would not be 
comparable as a flagship for 
NASA, ESA and the Japan 
Aerospace Exploration Agency 
(JAXA). 
A radical rethink of IXO might 
do it. A mission is defined by 
its science, not its hardware. 
IXO spanned all three decades 
of the X-ray band with a single 
mirror. But X-ray optics need 
focal lengths proportional to the 
photon energy reflected, so each 
sub-band would benefit from 
having a very different mirror. 
Turning IXO into a programme 
of independent small satellites, 
each optimized for one band, 
could be the answer. 
ESA, NASA and JAXA 
could each choose one and 
build it, without financial or 
technological interdependence, 
and space the launches over 
several years. 
The X-ray sky is full of 
complex sources with much 
interesting detail, but satellites 
dedicated to different energy 
bands would aim mostly at 
point sources, which have no 
discernable structure. Hence 
a further satellite with a high 
angular resolution imager would 
be needed. 
Some inter-agency agreement 
would help to achieve synergy, 
coordinating where they should 
be looking and allowing for 
multi-telescope proposals. 
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Bio-PIN could cut 
biobanking risks 
Donors of specimens to biobanks 
are entitled to respect for their 
privacy and protection from 
discrimination (Nature 469, 
156–157; 470, 169–70; 471, 
159–160; 2011). So long as the 
identity of a donor is on record, 
such protection cannot be 
guaranteed. A new system uses 
a biological PIN code to get 
around this problem. By keeping 
biological specimens and data 
anonymous, the ‘Bio-PIN’ also 
encourages donors by offering 
superior protection (J. J. Nietfeld 
et al. Nature Rev. Cancer 11, 
303–308; 2011). 
Unique to each donor, the 
Bio-PIN is based on one of their 
biological characteristics, such as 
a DNA fingerprint. It means that 
genetic or other data lodged in a 
biobank cannot be misused and 
that privacy is fully protected. 
As in financial banking, it 
allows two-way communication 
between bank and donor.
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‘No’ to ban on  
stem-cell patents
The advocate-general of the 
European Court of Justice has 
recommended the prohibition 
on ethical grounds of patents 
involving human embryonic 
stem cells (Nature 471, 280; 
2011). We write to express 
profound concern over 
this recommendation, as 
coordinators of multinational 
European stem-cell projects, 
working with both adult and 
embryonic stem cells.
Embryonic stem cells are 
cell lines, not embryos. They 
are derived using surplus in 
vitro fertilized eggs donated 
after fertility treatment and 
can be maintained indefinitely. 
As more than 100 established 
lines are now supplied through 
national and international 
cell banks, concern about 
commercialization of the human 
embryo is misplaced.
It is premature to suggest that 
human embryonic stem cells 
can be replaced in development 
of therapies. Although induced 
pluripotent stem cells offer 
additional possibilities, 
particularly for disease 
modelling, the reprogramming 
process is still imperfect. 
Scientists working in stem-
cell medicine will not be able to 
deliver clinical benefits without 
the involvement of biological 
industry. But innovative 
companies must have patent 
protection as an incentive to 
become active in Europe. 
The advocate-general’s 
opinion therefore represents a 
blow to years of effort to derive 
biomedical applications from 
embryonic stem cells in areas 
such as drug development 
and cell-replacement therapy. 
If implemented, European 
discoveries could be translated 
into applications elsewhere,  
at a potential cost to the 
European citizen. The advocate-
general’s opinion will now be 
Arab world needs  
its science diaspora 
As members of the Society for 
the Advancement of Science and 
Technology in the Arab World, 
we strongly believe that engaging 
the scientific diaspora — the 
research community of Arab 
scientists working abroad — is 
crucial for successful science in 
the region. 
In addition to the underlying 
political and societal problems 
and failed economic policies 
responsible for recent dramatic 
events in Arab countries, the 
failure of the educational systems 
is to blame. Academic institutions 
are not producing the skilled 
workforce necessary to meet local 
challenges and compete in global 
economies (Nature 470, 147–149; 
2011). The domino effect of 
the protests and change we are 
witnessing today, and its potential 
consequences for regional 
stability, indicate that correcting 
this shortcoming should be 
a regional and international 
priority. 
The international community 
must, through focused research 
and funding initiatives, assist in 
the areas of education, research 
and technology likely to have the 
highest impact on society. Arab 
scientists abroad represent a huge 
reservoir of talent for catalysing 
these efforts and strengthening 
partnerships with countries in 
the region. Investing in training 
and research programmes that 
harness the expertise, resources, 
networks and enthusiasm of 
these Arab scientists would 
contribute significantly to 
reversing the ‘brain drain’. And it 
would encourage local efforts to 
establish academic and research 
institutions to nurture creativity 
and entrepreneurship. 
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considered by members of the 
court. We trust that they will 
deliberate on the full implications 
before making a legally binding 
ruling.
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*A full list of signatories is 
available online at go.nature.
com/ryt4jv. Three authors declare 
competing financial interests (see 
go.nature.com/ryt4jv).
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